CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 13 enrolled
Drug / intervention
INCB7839drug
Likely dose
INCB7839 120 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04295759
NCT04295759Phase 1Completed
CompareCT.gov

A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3

Pediatric Brain Tumor Consortium·interventional·Posted Mar 4, 2020·Updated Jan 5, 2026

In Brief

A Phase 1 clinical trial evaluating INCB7839 for Glioblastoma Multiforme and 5 related conditions. Completed, enrolled 13 participants across 11 sites.

Detailed Summary

This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, DIPG, High-grade Astrocytoma NOS, CNS Primary Tumor, NOS (Malignant Glioma)
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), American Lebanese Syrian Associated Charities

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedMar 4, 2020
Enrollment StartJul 27, 2020
Primary CompletionDec 31, 2023
Study CompletionDec 1, 2024
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 6.3 years ago

Interventions

INCB7839drug

INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).